Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
- Three-Drug Combination Benefits Some Patients with Relapsed Multiple Myeloma
(Posted: 01/09/2015) - Interim results from an international, randomized phase III trial suggest that adding carfilzomib (Kyprolis®) to a standard treatment improves outcomes for patients with multiple myeloma whose cancer has relapsed. Participants in the study who received carfilzomib plus lenalidomide (Revlimid®) and dexamethasone lived a median of 8.7 months longer without the disease getting worse than patients who received lenalidomide and dexamethasone alone.
- Combining Two Types of Targeted Therapy Improves Survival in Some Patients with Advanced Melanoma
(Posted: 01/06/2015) - In two phase III trials, patients with metastatic melanoma whose tumors have specific mutations in the BRAF gene lived longer following treatment with dabrafenib (Tafinlar®), a BRAF inhibitor, plus trametinib (Mekinist®), a MEK inhibitor, than following treatment with a BRAF inhibitor alone.
- Nivolumab Improves Overall Survival in Patients with Metastatic Melanoma without a BRAF Mutation
(Posted: 01/06/2015) - Results from an international phase III trial show that nivolumab (Opdivo®) improves overall survival compared with the chemotherapy drug dacarbazine in patients with metastatic melanoma whose tumors do not have a mutation in the BRAF gene.
- Crizotinib Improves Progression-Free Survival in Some Patients with Advanced Lung Cancer (Updated)
(Updated: 12/04/2014) - Results from an international phase III trial show that crizotinib (Xalkori®) substantially extends progression-free survival in previously treated patients with advanced lung cancer whose tumors have a specific genetic mutation.
- Rituximab Retreatment after Disease Progression Is Comparable to Rituximab Maintenance Therapy in Patients with Low-Tumor Burden Follicular Lymphoma
(Posted: 10/02/2014) - In a randomized clinical trial, patients with low–tumor burden follicular lymphoma whose cancer responded to initial treatment with rituximab (Rituxan®) experienced similar disease control regardless of whether they subsequently received maintenance therapy with rituximab or were retreated with rituximab only when there was evidence of disease progression.